ALLO

Allogene Therapeutics, Inc.

2.36 USD
+0.01 (+0.43%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Allogene Therapeutics, Inc. stock is down -21.59% since 30 days ago. The next earnings date is Jul 31, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 June’s closed higher than May. 100% of analysts rate it a buy.

About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

  • Piper Sandler
    Fri May 31, 05:52
    buy
    initial
  • Oppenheimer
    Tue May 21, 07:59
    buy
    confirm